Navigation Links
All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke
Date:5/7/2009

Any are better than no treatment at all, study shows

THURSDAY, May 7 (HealthDay News) --Lowering blood pressure is essential for reducing the risk of heart disease and stroke, but which drugs are best has been a matter of debate.

Now, two new analyses attempt to answer that question.

Their conclusions: For heart attacks, all antihypertensive drugs work, with the exception of angiotensin receptor blockers (ARBs), probably because there aren't enough studies to confirm their benefit. For stroke, all antihypertensive drugs were better than placebo, but diuretics, ARBs or calcium channel blockers were significantly better than beta blockers or angiotensin-converting enzyme (ACE) inhibitors. Both reports were presented Wednesday at the American Society of Hypertension's annual meeting, in San Francisco.

"Physicians and patients should be reassured that, based on all the world's literature, sliced and diced in many ways, subjected to two separate and distinct types of meta-analyses, antihypertensive drugs do reduce the risk of the two most feared endpoints related to hypertension: heart disease and stroke," said lead researcher Dr. William J. Elliott, a professor of preventive medicine, internal medicine and pharmacology at Rush Medical College in Chicago.

For the first study, Elliott's team analyzed data from 57 trials that looked at treatment for high blood pressure and the reduction of heart attack risk.

The researchers found that, except for ARBs, all drugs were significantly better than placebo or no treatment in lowering blood pressure and reducing the risk of heart disease. Among all the drugs, ACE inhibitors were slightly better, however, the difference was not statistically significant.

These findings confirm other research that has shown that ARBs may not be as effective at preventing heart attack as other blood pressure drugs, and that ACE inhibitors are especially effective at preventing heart disease. That benefit may be due to other effects of the drug, not just its ability to lower blood pressure, the researchers noted.

In addition, this study may help end the debate about which diuretics are best. Elliott's group found that there was no difference among different diuretics in preventing heart attack or sudden cardiac death.

"We presume the lack of significance with ARBs stems from the fact that this is the newest class of drugs, and therefore fewer trials involving fewer patients having fewer coronary heart disease events [half to a third of other classes] limits the statistical power of the analysis," Elliott said.

In the second report, Elliott's team analyzed 60 clinical trials involving 279,371 patients. In their analysis, the researchers also found that blood pressure-lowering drugs were significantly better than placebo or no treatment in reducing the risk of stroke.

Starting treatment with a diuretic reduced the risk of stroke by 55 percent, while beta blockers reduced the risk by about 22 percent, and ACE-inhibitors reduced the risk by about 16 percent. Starting treatment with a diuretic, ARB or calcium channel blocker did not produce significantly different results, the researchers added.

As with the other analyses, there was no significant difference between diuretics in preventing stroke.

"All antihypertensive drug classes are significantly better than placebo/no treatment to reduce the risk of stroke," Elliott said.

Although there are some differences in stroke prevention between the different antihypertensives, the data suggest that diuretics and calcium channel blockers may be more effective in preventing stroke than heart attack.

Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, does not think these studies answer the question of which blood pressure medication is best. The bottom line is that lowering blood pressure by any means is important in reducing the risk for heart attack and stroke.

"Patients with hypertension are at increased risk for heart attacks and strokes, and reducing blood pressure to goal levels is essential to lower this risk," Fonarow said. "Clinicians and researchers continue to debate whether there are important differences among the specific medications in reducing risk."

These two studies involved pooling together different randomized trials to explore the relative differences for coronary heart disease and stroke risk with different classes of antihypertensive agents, Fonarow said.

"Despite the large number of studies and patients, due to differences in the on-treatment blood pressures achieved in the various studies, something which was not controlled for in these analyses, no firm conclusions can be drawn," Fonarow said. "Furthermore, recent large scale randomized clinical trials where similar blood pressures have been achieved provide entirely different conclusions."

"Achieving and maintaining control of blood pressure to goal levels with lifestyle changes and, when indicated, anti-hypertensive medications is far more important than which specific anti-hypertensive medication is selected," he said.

More information

For more on heart disease and stroke, visit the American Heart Association.



SOURCES: William J. Elliott, M.D., Ph.D., professor, preventive medicine, internal medicine and pharmacology, Rush Medical College, Chicago; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; May 6, 2009, presentations, American Society of Hypertension annual meeting, San Francisco


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Angel”: ... the Lord has set out for each of his children. “The Angel” is the ... School of Music in New York City, and impassioned writer. , When asked of ...
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
(Date:1/19/2017)... (PRWEB) , ... January 20, 2017 , ... Today, the ... to participate in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who ... patients. APMs are an important part of the Administration’s effort to build a ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy ... enhancement of their 503A compounding pharmacy located in Ocala, Florida. , Meeting ... and patients throughout the United States for high-quality human anti-aging and wellness ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... January 19, 2017 According to a study ... is set to witness a CAGR of 6.5% during the forecast ... will continue to be the leading market for cryotherapy globally ... ... emphasizing on ensuring affordable and adequate supply of gas in order ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, Inc. ... company specializing in the treatment of non-melanoma skin ... with superficial radiation therapy, today announced that it ... 2016 financial results on Thursday, February 2, 2017 after ... hold a conference call with the investment community ...
Breaking Medicine Technology: